CDK4 and neoplasm: In senescent melanoma, CDK4/6 inhibitors increase the secretion of IFN‐γ and IFN‐β, attracting infiltrating CD8+ T cells into the TME and sensitising tumour cells to immune checkpoint inhibitors.45